Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

被引：0
|
作者：
Thomas E. Stinchcombe
Mark A. Socinski
Christine M. Walko
Bert H. O’Neil
Frances A. Collichio
Anastasia Ivanova
Hua Mu
Michael J. Hawkins
Richard M. Goldberg
Celeste Lindley
E. Claire Dees
机构：
[1] University of North Carolina,Department of Hematology/Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center
[2] University of North Carolina,School of Pharmacy
[3] Lineberger Comprehensive Cancer Center,Department of Biostatics
[4] Abraxis BioScience,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Dose-limiting toxicity; Maximum tolerated dose; Melanoma; Non-small-cell lung cancer; Small-cell lung cancer; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 766
页数：7
相关论文
共 50 条
  • [21] Systemic Nanoparticle Albumin-bound Paclitaxel (ABI-007) for prevention of In-stent ReSTenosis (SNAPIST-I): A first in man safety and dose finding study
    McDonald, J. E.
    Klinke, W. P.
    Margolis, J.
    Hilton, J. D.
    Heuser, R.
    Waksman, R.
    Virmani, R.
    Fajadet, J.
    EUROPEAN HEART JOURNAL, 2005, 26 : 696 - 696
  • [22] A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies.
    Nyman, DW
    Campbell, KJ
    Hersh, E
    Richardson, K
    Patrick, K
    Trieu, V
    Desai, N
    Von Hoff, DD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 133S - 133S
  • [23] Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer
    Masashi Ando
    Kan Yonemori
    Noriyuki Katsumata
    Chikako Shimizu
    Taizo Hirata
    Harukaze Yamamoto
    Kenji Hashimoto
    Mayu Yunokawa
    Kenji Tamura
    Yasuhiro Fujiwara
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 457 - 465
  • [24] Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer
    Ando, Masashi
    Yonemori, Kan
    Katsumata, Noriyuki
    Shimizu, Chikako
    Hirata, Taizo
    Yamamoto, Harukaze
    Hashimoto, Kenji
    Yunokawa, Mayu
    Tamura, Kenji
    Fujiwara, Yasuhiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 457 - 465
  • [25] Phase I study of cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel (ABI-007) in solid tumors.
    Ibrahim, NK
    Ellerhorst, JA
    Theriault, RL
    Rivera, E
    Esmaeli, B
    Soon-Shiong, P
    Benjamin, RS
    Hortobagyi, GN
    CLINICAL CANCER RESEARCH, 2000, 6 : 4580S - 4580S
  • [26] Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
    Desai, N
    Trieu, V
    Yao, ZW
    Louie, L
    Ci, S
    Yang, A
    Tao, CL
    De, T
    Beals, B
    Dykes, D
    Noker, P
    Yao, R
    Labao, E
    Hawkins, M
    Soon-Shiong, P
    CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1317 - 1324
  • [27] Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
    Ibrahim, NK
    Desai, N
    Legha, S
    Soon-Shiong, P
    Theriault, RL
    Rivera, E
    Esmaeli, B
    Ring, SE
    Bedikian, A
    Hortobagyi, GN
    Ellerhorst, JA
    CLINICAL CANCER RESEARCH, 2002, 8 (05) : 1038 - 1044
  • [28] A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladde
    Smith, D. C.
    Grivas, P.
    Daignault, S.
    Hafez, K.
    Wood, D. P.
    Lee, C. T.
    Montie, J. E.
    Weizer, A. Z.
    Montgomery, J.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [29] Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane®) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC):: A phase II trial of the NSABP foundation research programs (FRP).
    Robidoux, A.
    Buyse, M.
    Buzdar, A.
    Geyer, C. E.
    Pajon, E.
    DiNunno, L.
    Desai, A.
    Fehrenbacher, L.
    Kuerer, H.
    Liles, D.
    Paik, S.
    Mamounas, E.
    Wolmark, N.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S147 - S147
  • [30] Radiosensitizing effects of ABI-007, a novel solvent-free nanoparticle albumin-bound (NAB) paclitaxel: Preclinical studies on tumor and normal tissue models
    Wiedenmann, N.
    Valdecanas, D.
    Hunter, N.
    Farrar, D.
    Milas, L.
    Mason, K. A.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 65 - 66
12345